Procyon Corporation

What they do

Procyon, through its wholly-owned subsidiaries AMERX Health Care Corporation and Sirius Medical Supply, develops and markets proprietary medical products for the treatment of pressure ulcers, wounds, dermatitis, and other skin problems. Products are sold through distributors to hospitals, wound care clinics, nursing homes, home health agencies, and retailers. Sirius has no material operations. Major product lines include AMERIGEL, HELIX3 Bioactive Collagen, EXTREMIT-EASE Compression Garment, and Advantagen Surgical Collagen.

Revenue drivers

• AMERIGEL product line — Core foundation for growth; includes Hydrogel Wound Dressing, Post Op Surgical Kits, Saline Wound Wash, Care Lotion, and Barrier Lotion.
• HELIX3 Bioactive Collagen — Collagen Powder, Collagen Matrix, and Collagen Gel (added in 2022) addressing wound care market segments.
• AMERX wound care line — Includes Calcium Alginate, Foam, Gauze, Hydrocolloid Dressings, and Wound Care Kits, plus Rolled Gauze kits and Retention tape added in 2022.
• EXTREMIT-EASE Compression Garment — Patented in June 2022; expands beyond historical niche into compression therapy.

Recent performance

In fiscal 2024 (year ending June 30, 2024), revenue was $5.0 million, up modestly from $4.7 million in fiscal 2023, but net income was a loss of $341,140 compared to a smaller loss of $50,245 in the prior year. Operating cash flow was negative $61,251 in fiscal 2024. Quarterly revenue trended upward from $1.2 million in the quarters ending September 2023 through March 2024 to $1.4 million in June 2024. At June 30, 2024, total assets were $3.2 million, total liabilities were $917,122, and shareholder equity was $2.3 million.

Strategy

Management plans to continue product line expansion in fiscal 2025, as stated in the 10-K. Recent additions include HELIX3 Collagen Gel (fiscal 2023) and Advantagen surgical collagen (fiscal 2022). The company emphasizes obtaining Medicare reimbursement codes for its products, which are assigned by PDAC, and believes these codes are beneficial. R&D spending was approximately $30,100 in the past fiscal year, focused on new product offerings. Product lines are protected by trade secrets, registered trademarks, and one patent (EXTREMIT-EASE).

Risks

• Small size and limited capital — With only $121,528 in cash as of early 2020 and small annual revenue, the company has limited financial flexibility.
• Operating losses — The company has reported net losses in three of the last five fiscal years, including a $341,140 loss in fiscal 2024.
• Concentration in wound care niche — Revenue depends heavily on AMERX's wound and skin care products, which are subject to competitive and reimbursement pressures.
• Dependence on key personnel — Historical dependence on the late CEO John C. Anderson and the small size of the organization creates key-person risk.

Outlook

Management states it will continue to evaluate product line expansion in fiscal 2025. The company expects its Medicare reimbursement codes to remain beneficial for customers. No specific revenue or earnings guidance was provided in the filings.